Sponsor content
216 result(s) found, displaying 41 to 50
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Takeda Pharmaceuticals Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Takeda Pharmaceuticals Australia Pty Ltd - Subcutaneous/intramuscular injection set, medicated.
-
Prescription medicine registrationActive ingredients: lanadelumab.
-
Australian Public Assessment Report (AusPAR)Adcetris (brentuximab vedotin) has been approved for the treatment of Hodgkin lymphoma in patients with previously untreated CD30+ Stage III or Stage IV Hodgkin lymphoma.
-
Guanfacine 1 TAKEDA guanfacine (as hydrochloride) 1 mg modified release tablet blister pack (395368)
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 1 TAKEDA guanfacine (as hydrochloride) 1 mg modified release tablet blister pack. -
Guanfacine 2 TAKEDA guanfacine (as hydrochloride) 2 mg modified release tablet blister pack (395369)
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 2 TAKEDA guanfacine (as hydrochloride) 2 mg modified release tablet blister pack. -
Guanfacine 3 TAKEDA guanfacine (as hydrochloride) 3 mg modified release tablet blister pack (395373)
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Guanfacine 3 TAKEDA guanfacine (as hydrochloride) 3 mg modified release tablet blister pack.